Publications by authors named "Taylor A Gentile"

10Publications

The kappa opioid receptor agonist U50,488H did not affect brain-stimulation reward while it elicited conditioned place aversion in mice.

BMC Res Notes 2020 Aug 14;13(1):384. Epub 2020 Aug 14.

Center for Substance Abuse Research (CSAR) & Department of Pharmacology, Lewis Katz School of Medicine at Temple University, 3500 North Broad Street, MERB 851, Philadelphia, PA, 19140, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13104-020-05227-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429879PMC
August 2020

Cocaine abuse and midbrain circuits: Functional anatomy of hypocretin/orexin transmission and therapeutic prospect.

Brain Res 2020 03 20;1731:146164. Epub 2019 Feb 20.

Center for Substance Abuse Research, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brainres.2019.02.026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702109PMC
March 2020

Synthetic cathinone MDPV enhances reward function through purinergic P2X7 receptor-dependent pathway and increases P2X7 gene expression in nucleus accumbens.

Drug Alcohol Depend 2019 04 31;197:22-27. Epub 2019 Jan 31.

Center for Substance Abuse Research, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA; Department of Pharmacology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drugalcdep.2018.12.022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447078PMC
April 2019

Phosphoproteomic approach for agonist-specific signaling in mouse brains: mTOR pathway is involved in κ opioid aversion.

Neuropsychopharmacology 2019 04 20;44(5):939-949. Epub 2018 Jul 20.

Center for Substance Abuse Research & Department of Pharmacology, Temple University Lewis Katz School of Medicine, Philadelphia, PA, 19140, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41386-018-0155-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462019PMC
April 2019

Effects of Suvorexant, a Dual Orexin/Hypocretin Receptor Antagonist, on Impulsive Behavior Associated with Cocaine.

Neuropsychopharmacology 2018 04 25;43(5):1001-1009. Epub 2017 Jul 25.

Center for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/npp.2017.158DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5854790PMC
April 2018

Suvorexant, an orexin/hypocretin receptor antagonist, attenuates motivational and hedonic properties of cocaine.

Addict Biol 2018 01 17;23(1):247-255. Epub 2017 Apr 17.

Center for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/adb.12507DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5645207PMC
January 2018

Nicotinic receptor blockade decreases fos immunoreactivity within orexin/hypocretin-expressing neurons of nicotine-exposed rats.

Behav Brain Res 2016 11 1;314:226-33. Epub 2016 Aug 1.

Center for Substance Abuse Research, Lewis Katz School of Medicine at Temple University, Philadelphia, PA19140, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbr.2016.07.053DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817994PMC
November 2016